 |
市場調查報告書
商品編碼
1567138
利伐沙班市場：按適應症、按劑型、按患者類型、按分銷管道、按地區Rivaroxaban Market, By Indication (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism, and Others), By Formulation, By Patient Type, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
利伐沙班的全球市場預計到2024年為1,672萬美元，預計到2031年將達到2,611萬美元，2024年至2031年的複合年成長率為6.6%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2023年 | 2024年市場規模 | 1672萬美元 |
| 實際資料 | 2019年至2023年 | 預測期 | 從2024年到2031年 |
| 預測 2024-2031 年複合年成長率： | 6.60% | 2031年價值預測 | 2611萬美元 |
圖：2024 年利伐沙班市場佔有率（%），依地區分類
由於全球深層靜脈栓塞症和肺動脈栓塞盛行率不斷上升，利伐沙班的全球市場在過去十年中一直穩步成長。 Rivaroxaban 是一種口服抗凝血劑，可作為凝血途徑中 Xa 因子的抑制劑。利伐沙班在需要抗凝血治療的患者中用作Warfarin的抗凝血替代品。此藥最常用於降低非瓣膜性心房顫動患者發生中風和全身性栓塞的風險，治療深層靜脈栓塞症和肺動脈栓塞，以及預防靜脈血栓栓塞症的復發。隨著人們對新型口服抗凝血劑益處的認知不斷提高，以及受目標疾病影響的患者數量不斷增加，利伐沙班市場預計在未來幾年將繼續快速擴張。
市場動態：
全球利伐沙班市場成長的驅動力是老年人口的增加，老年人口更容易發生血栓性栓塞症，相對於Warfarin等傳統藥物，人們對新型口服抗凝血劑的偏好日益增加，這是外科手術的增加。然而，與學名藥相比，利伐沙班治療的高昂成本是限制其廣泛使用的主要因素。從積極的一面來看，臨床試驗正在進行中，以評估利伐沙班的其他適應症，新年齡層的核准預計將創造新的機會。此外，開發適合特定患者類型的改良劑型可能有助於克服高成本帶來的挑戰。
本研究的主要特點
- 本報告對全球利伐沙班市場進行了詳細分析，並提出了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。
- 它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
- 基於公司亮點、產品系列、主要亮點、財務表現和策略等參數的全球利伐沙班市場的主要企業概況。
- 該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 全球利伐沙班市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
- 透過分析全球利伐沙班市場時所使用的各種策略矩陣，將有助於相關人員做出決策。
目錄
第1章 研究目的與前提
- 研究目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章市場動態、法規與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管場景
- 產品發布/核准
- PEST分析
- 波特分析
- 併購場景
第4章 全球利伐沙班市場，依適應症分類，2024-2031 年（百萬美元）
- 心房顫動
- 深層靜脈栓塞症（DVT）
- 肺動脈栓塞（PE）
- 預防靜脈血栓栓塞症（VTE）
- 其他（急性冠狀動脈症候群等）
第5章全球利伐沙班市場，按劑型，2024-2031 年，（百萬美元）
- 藥片
- 暫停
第6章 全球利伐沙班市場，依病患類型，2024-2031 年（百萬美元）
- 成人
- 小兒科
第 7 章 全球利伐沙班市場，依通路分類，2024-2031 年（百萬美元）
- 醫院和診所
- 零售藥房
- 網路藥房
第8章全球利伐沙班市場，按地區，2019-2031，價值（百萬美元）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東地區
- 非洲
- 南非
- 北非
- 中部非洲
第9章 競爭格局
- Bayer AG
- Janssen Pharmaceuticals, Inc.
- Interquim SA
- Natco Pharma
- Mylan NV
- Sandoz（a Novartis division）
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Hetero Labs Limited
- Fresenius Kabi AG
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals
- Reddy's Laboratories
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Pfizer Inc.
- Eisai Co., Ltd.
- Amgen Inc.
第10章分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第11章 參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
簡介目錄
Product Code: CMI1962
Global Rivaroxaban Market is estimated to be valued at USD 16.72 Mn in 2024 and is expected to reach USD 26.11 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 16.72 Mn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 6.60% | 2031 Value Projection: | US$ 26.11 Mn |
Figure. Rivaroxaban Market Share (%), By Region, 2024
The global Rivaroxaban market has been growing steadily over the past decade on the back of rising prevalence of deep vein thrombosis and pulmonary embolism disorders globally. Rivaroxaban is an oral anticoagulant that acts as an inhibitor of factor Xa in the blood coagulation pathway. It has emerged as a preferred alternative to warfarin for patients requiring anticoagulation therapy due to advantages such as fixed dosing without need for frequent monitoring. The drug is most commonly used to reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and reduce recurrence of venous thromboembolism. With growing awareness about benefits of novel oral anticoagulants and increasing patient pool affected by target diseases, the rivaroxaban market is anticipated to continue expanding rapidly over the coming years.
Market Dynamics:
The global rivaroxaban market growth is driven by rising geriatric population who are more prone to thromboembolic disorders, growing preference for novel oral anticoagulants over traditional drugs like warfarin, and increasing number of surgical procedures performed worldwide. However, high costs associated with rivaroxaban therapy compared to generic drugs is a major factor limiting its widespread adoption. On the positive side, ongoing clinical trials evaluating rivaroxaban for additional indications and approval for new age groups are expected to create new opportunities. Moreover, development of modified dosage forms suited for specific patient types could help overcome challenges posed by high costs.
Key features of the study:
- This report provides in-depth analysis of the global rivaroxaban market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global rivaroxaban market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Johnson & Johnson, Pfizer, Bayer, and Sanofi
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global rivaroxaban market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global rivaroxaban market.
Detailed Segmentation:
- By Indication Insights (Revenue, USD Mn, 2019 - 2031)
- Atrial Fibrillation
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Prophylaxis of Venous Thromboembolism (VTE)
- Others (Acute Coronary Syndrome, etc.)
- By Formulation Insights (Revenue, USD Mn, 2019 - 2031)
- Tablets
- Suspension
- By Patient Type Insights (Revenue, USD Mn, 2019 - 2031)
- Adults
- Pediatrics
- By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
- Hospitals and Clinics
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Bayer AG
- Janssen Pharmaceuticals, Inc.
- Interquim SA
- Natco Pharma
- Mylan N.V.
- Sandoz (a Novartis division)
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Hetero Labs Limited
- Fresenius Kabi AG
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals
- Reddy's Laboratories
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Pfizer Inc.
- Eisai Co., Ltd.
- Amgen Inc.
Table of Contents
1. RESEARCH OBJECTIVES AND ASSUMPTIONS
- Research Objectives
- Assumptions
- Abbreviations
2. MARKET PURVIEW
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Rivaroxaban Market, By Indication
- Global Rivaroxaban Market, By Formulation
- Global Rivaroxaban Market, By Patient Type
- Global Rivaroxaban Market, By Distribution Channel
- Global Rivaroxaban Market, By Region
3. MARKET DYNAMICS, REGULATIONS, AND TRENDS ANALYSIS
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Rivaroxaban Market, By Indication, 2024-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Atrial Fibrillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Deep Vein Thrombosis (DVT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Pulmonary Embolism (PE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Prophylaxis of Venous Thromboembolism (VTE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others (Acute Coronary Syndrome, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
5. Global Rivaroxaban Market, By Formulation, 2024-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Global Rivaroxaban Market, By Patient Type, 2024-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Global Rivaroxaban Market, By Distribution Channel, 2024-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
8. Global Rivaroxaban Market, By Region, 2019 - 2031, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2019 - 2031, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
9. COMPETITIVE LANDSCAPE
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Interquim SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Natco Pharma
- Mylan N.V.
- Sandoz (a Novartis division)
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Hetero Labs Limited
- Fresenius Kabi AG
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals
- Reddy's Laboratories
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Pfizer Inc.
- Eisai Co., Ltd.
- Amgen Inc.
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
02-2729-4219
+886-2-2729-4219
心率穩定器市場：按產品類型、用途、患者、最終用戶、應用、技術 - 全球預測 2025-2030
心血管藥物市場：按藥物類別、適應症、患者人口統計、最終用戶、給藥途徑、分銷管道 - 2025-2030 年全球預測
鹽酸阿米洛利市場：按產品類型、應用、最終用戶、分銷管道 - 2025-2030 年全球預測
全球心血管藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測
聚二甲醚市場：按配方、分銷管道和用戶分類 - 2024-2030 年全球預測
硫酸麻黃鹼市場：依純度、給藥方式、依適應症、依地區、機會、預測，2017-2031年
心血管藥物市場：按藥物類型、適應症、給藥途徑、購買型態和最終用戶分類 - 全球預測 2024-2030
血管水腫治療藥物市場：按藥物類型、給藥途徑和最終用戶分類 - 全球預測 2024-2030
心血管藥物市場 - 2023-2031 年全球產業分析、規模、佔有率、成長、趨勢與預測
全球心跳穩定器市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會與預測，按產品類型、按應用、最終用戶按地區和競爭細分
▼